INITIAL RESULTS IN RECURRENT BRAIN GLIOBLASTOMAS MANAGEMENT WITH MAXIMAL SAFE RESECTION FOLLOWED BY INTAOPERATIVE BALLOON ELECTRONIC BRACHYTERAPY

Brain glioblastomas (GBM) are notorious for their early local recurrence despite of standard combined treatment. Technologies for recurrent GBM management require further development and research. Resection of malignant gliomas must be followed by an adjuvant treatment. Intraoperative balloon electronic brachytherapy (IBEB) has been recently introduced into clinical practice and could be successfully applied to recurrent GBM management. This article presents the initial results of recurrent GBM management with maximal safe resection followed by IBEB. Material and methods. Patients (n = 11) with recurrent GBM after standard combined treatment were managed with maximal safe microsurgical resection followed by IBEB. The follow-up period after IBEB ranged from 1 to 30 months. Results. The median overall survival for the entire study group of patients included in the statistical analysis (n = 9) was 27 months (range 17–47 months). In the subgroup of patients (n = 4) with contrast-enhanced tumor MRI volume after resection ≤ 2.5 cm3, the median local progression free survival (locPFS) was 21.25 months (range 10–30 months). Conclusion. Initial results in recurrent brain GBMs management with resection followed by IBEB seems to be promising, especially in case of contrast-enhanced tumor volume detected on MRI after resection is less than 2.5 cm3 without signs of multifocal tumor growth.

1. Goryaynov S.A., Gol’dberg M.F., Golanov A.V., Zolotova S.V., Shishkina L.V., Ryzhova M.V., Pitskhelauri D.I., Zhukov V.Yu., Usachev D.Yu., Belyaev A.Yu., Kondrashov A.V., Shurkhay V.A., Potapov A.A. The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R132H). Voprosy neyrokhirurgii imeni Nikolaya Nikolaevicha Burdenko = Burdenko’s Journal of Neurosurgery. 2017; 81 (3): 5–16. [In Russian]. doi: 10.17116/neiro20178135-16.

2. Krivoshapkin A.L., Sergeev G.S., Gaytan A.S., Kurbatov V.P., Kiselev R.S., Kalneus L.E. Impact of pre- and postoperative tumor volumetric data on survival of patiens with glioblastomas. Vestnik nevrologii, psikhiatrii i neyrokhirurgii = Bulletin of Neurology, Psychiatry and Neurosurgery. 2016; (6): 59–67. [In Russian].

3. Krivoshapkin A.L., Shayman L.М., Gaytan A.S., Sergeev G.S., Abdullaev О.А., Islim N., Marmazeev I.V. A method for the treatment of malignant gliomas of the brain. Patent 2684019 RF; Published 22.03.2018. [In Russian].

4. Salim N., Krivoshapkin A.L., Gaytan A.S., Marmazeev I.V., Abdullaev О.А., Sergeev G.S., Schоnus D.C. The use of intraoperative radiotherapy in patients with recurrent high-grade gliomas. J. Malignant Tumors. 2017; 7 (3): 110. [In Russian].

5. Barney C., Shukla G., Bhamidipati D., Palmer J.D. Re-irradiation for recurrent glioblastoma multiforme. Chin. Clin. Oncol. 2017; 6 (4): 36. doi: 10.21037/cco.2017.06.18.

6. D’Amico R.S., Englander Z.K., Canoll P., Bruce J.N. Extent of resection in glioma: A review of the cutting edge. World Neurosurg. 2017; 103: 538–549. doi: 10.1016/j.wneu.2017.04.041.

7. Do V., Gebski V., Barton M.B. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother. Oncol. 2000; 57 (2): 131–136.

8. Epstein M.S., Silverstein M.J., Lin K., Kim B., de Leon C., Khan S., Guerra L.E., Snyder L., Coleman C., Lopez J., Mackintosh R., Chen P. Acute and chronic complications in patients with ductal carcinoma in situ treated with intraoperative radiation therapy. Breast J. 2016; 22 (6): 630–636. doi: 10.1111/tbj.12650.

9. Giordano F.A., Abo-Madyan Y., Brehmer S., Herskind C., Sperk E., Schneider F., Clausen S., Welzel G., Schmiedek P., Wenz F. Intraoperative radiotherapy (IORT) – a resurrected option for treating glioblastoma? Transl. Cancer Res. 2014; 3 (1): 94–105. doi: 10.3978/j.issn.2218-676X.2014.01.03.

10. Hervey-Jumper S.L., Berger M.S. Maximizing safe resection of low- and high-grade glioma. J. Neurooncol. 2016; 130 (2): 269–282. doi: 10.1007/s11060-016-2110-4.

11. Johnson D.R., Omuro A.M.P., Ravelo A., Sommer N., Guerin A., Ionescu-Ittu R., Shi S., Macalalad A., Uhm J.H. Overall survival in patients with glioblastoma before and after bevacizumab approval. Curr. Med. Res. Opin. 2018; 34 (5): 813–820. doi: 10.1080/03007995.2017.1392294.

12. Kelly С., Majewska P., Ioannidis S., Raza M.H., Williams M. Estimating progression-free survival in patients with glioblastoma using routinely collected data. J. Neurooncol. 2017; 135 (3): 621–627. doi: 10.1007/s11060-017-2619-1.

13. Krivosheya D., Prabhu S.S., Weinberg J.S., Sawaya R. Technical principles in glioma surgery and preoperative considerations. J. Neurooncol. 2016; 130 (2): 243–252. doi: 10.1007/s11060-016-2171-4.

14. Rapp M., Baernreuther J., Turowski B., Steiger H.J., Sabel M., Kamp M.A. Recurrence pattern analysis of primary glioblastoma. World Neurosurg. 2017; 103: 733–740. doi: 10.1016/j.wneu.2017.04.053.

15. Stupp R., Mason W.P., van den Bent M.J. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005; 352 (10): 987–996. doi: 10.1056/NEJMoa043330.

16. Van Linde M.E., Brahm C.G., de Witt Hamer P.C.3, Reijneveld J.C., Bruynzeel A.M.E., Vandertop W.P., van de Ven P.M.6, Wagemakers M., van der Weide H.L., Enting R.H., Walenkamp A.M.E., Verheul H.M.W. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J. Neurooncol. 2017; 135 (1): 183–192. doi: 10.1007/s11060-017-2564-z.